A
standing ovation of some 1200 people bidding farewell to the speakers
was the closing act of the first International Conference on
Complementary and Alternative Treatments in Cancer. The conference was
held on May 14 and 15, 2005, in the auditorium of the Madrid Palace of
Congress and Exhibitions in Spain. Hundreds of doctors—including more
than 100 oncologists, biologists, specialist engineers in
electromedicine, representatives of numerous laboratories, alternative
health care professionals, and other experts—left with the conviction
that as the first of its kind in the world, this event will epitomize
the before and after of cancer treatment.
The
conclusion was resounding: each year the number of people who die of
cancer increases and although the pharmaceutical industry periodically
puts out unrepresentative information, with the media's involvement or
ignorance, it is evident that orthodox cancer treatments such as
chemotherapy, radiotherapy, and surgery have failed. Therefore, the
time has come for a sweeping change in therapies for this illness.
The
opening report of the congress demolished all opposition by showing
beyond any doubt the scientific validity of all the alternative
treatments presented, which are innocuous and have noticeably higher
efficacy than radiotherapy and chemotherapy. This cast serious doubt on
the credibility of those who try to scorn alternative treatments.
This
fact was established in many presentations, using the same arguments as
orthodox clinical oncology studies that adhere to a protocol. This
overcame all challenges. Unlike traditional congresses, the palace's
auditorium was completely filled during the 15 presentations, all of
which were interrupted several times by prolonged approving applause.
Those
who attended were amazed by the excellence of the presentations, their
medical and scientific quality, and the human value of the lecturers.
However, four of the presentations stand out for particularly poignant
moments. The first moment came with the participation of Dr Salvador
Capistrán, who is very well known in Mexico and who could not curb his
emotion during the lecture, transmitting it to the hundreds present.
The
long ovation that closed his lecture prompted a number of those
attending to ask the organizers whether it could be repeated.
Unfortunately, this was not possible owing to the event's very tight
agenda. Dr Capistrán's large medical staff in Mexico is treating cancer
with excellent results using antigen vaccines processed from the
patient's urine.
The second moment
occurred when, during the presentation by Dr Jaroslaw W. Nowicky,
Director of the Ukrainian Anti-Cancer Institute of Vienna (Austria),
the congress organizers announced his nomination by colleagues for the
Nobel Prize in Chemistry. When it is injected intravenously in
therapeutic doses, Ukrain destroys carcinogenic cells by stimulating
their ‘suicide’ or apoptosis without affecting healthy cells. Ukrain
has been the object of investigations and studies by 159 scientists
from 56 universities in 26 different countries. Results have been
presented in 220 international scientific congresses and symposia.
Details of the properties of Ukrain have been published in 192
scientific publications. Thus, an enthusiastic response ended Dr
Nowicky's presentation.
The third
momentous occasion was when the council of the Discovery Salud journal,
organizer and sponsor of this congress, announced that it would propose
Dr Ryke Geerd Hamer for the Nobel Prize in Medicine. ‘Those legally
entitled to do so will not do it,’ said José Antonio Campoy, Director
of Discovery Salud.
In fact, the
prize's criteria restrict the possibility of nomination and it is
obvious that candidates can only be proposed by those who belong to the
system. What Hammer proposes is not, in any way, in the interests of
those opposed to him, who live from the business of making money out of
health, and thus he will not be taken into consideration. So, although
the policy does not allow it, we will try to bring about his nomination
through popular request. Therefore, we will facilitate, for this
reason, a place for this at our web site www.dsalud.com. This initiative will be communicated to him today as his birthday is tomorrow. The idea was greeted with lengthy applause.
The
final choice among many outstanding moments during the congress was the
closing lecture concerning Bio-Bac. In an inspired presentation, Dr
Fermín Moriano recounted the ignominious treatment of this
product—which started 20 years ago in 1985, and which should have sent
several public servants to prison—and also enumerated the numerous
preclinical and clinical studies of Bio-Bac, including those undertaken
at first-line centers in Germany and Belgium (together with Phase I,
II, and III trials in osteoarthritis and AIDS).
Facts
emerged about the public administration's two-and-a-half-year
‘Operation Witchcraft’ against Bio-Bac; the health ministry's refusal
to furnish an official answer concerning the clinical studies in its
hands, as requested by the judge; and the authorities' initial claim
that the studies did not exist and later allegation that they had been
forged. The lecture triggered a standing ovation for the owner of the
product, Rafael Chacón, when he was introduced by the moderator.
It
must be added that all the health professionals present at the congress
openly expressed their satisfaction with all the presentations and with
developments at the event. These included the participation of
Aleksandra Niedzwiecki, Doctor of Biochemistry, Executive Vice
President and Investigation Director of Matias Rath Inc. (USA) and
formerly Director of Cardiovascular Investigation at the Linus Pauling
Science and Medicine Institute in Palo Alto, whose lecture dealt with
‘New and effective focus for cellular medicine concerning metastasis
and cancer growth’. Dr Eduardo Sanz, biologist, graduate in molecular
oncology, Alfred Gilman's collaborator in the construction of the
proteome, and currently scientific adviser to the Catalysis Laboratory,
spoke about ‘Virus factors in the development of tumors: new
therapeutic alternatives’. Dr Hans Peter Weber, member of the
consulting board of the International Society for the Investigation of
Cellular Therapy and of the International Academy of Preventive
Medicine, presented ‘Effectiveness in the treatment of tumors with
electrotherapy: scientific basis and real cases’. The world-renowned
Colombian Dr Jorge Carvajal, creator of Sintergetic Medicine, who has
trained more than a thousand doctors from 11 different countries, spoke
about ‘Bio-energetic treatment of cancer’. The Uruguayan Dr Bernardo
Udaquiola, member of the National Oncology Institute of Uruguay,
presented ‘Phototherapeutic and homeopathic treatment of cancer: Green
Sap and Onconat’. The Ecuadorian Dr Edwin Ceballos, oncology and
radiotherapy specialist, creator of the Biological Immune Response
Modulator (BIRM), which has been approved by the FDA as an orphan
treatment in pancreatic cancer, gave an account of ‘BIRM in AIDS and
cancer’. Professor Panos T. Pappas, international expert in
electromagnetism and electrodynamics and adviser to the most important
journals in these areas of expertise, spoke about ‘The Pap-imi
treatment in cancer’. The Director of the Spanish Center for
Investigation and Diagnosis INSAODYT, Juan Prada, lectured on ‘The
possibilities of the bio-hematological exam’, a method developed by his
father, Dr Pascual Prada, 40 years ago, as an essential complementary
diagnosis in cancer treatments.
José
Olalde, jointly with Drs Meyer Magarici, José Gregorio Guiadas, Alberto
Muhammad, and Antonio Salom, presented ‘The Systemic Theory of Living
Systems applied to cancer and results’. José Ramón Llorente, President
of the Spanish Orthomolecular Nutrition Association, talked on ‘The
treatment of cancer with orthomolecular medicine’. The Italian expert
Marco Pfister substituted for the speaker of honor of the congress, Dr
Hammer. The Discovery Salud organization announced the following next
steps: the publication of a book in September with all the information
presented during the congress, as well as all other therapies published
in the journal in the past 3 years, and the launch of a free health
information service through the Internet with an initial projection of
1.5 million users.